Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C

Clinical Chemistry

Volumn 50, Issue 8, 2004, Pages 1344-1355

  Poynard, Thierry ^a   Munteanu, Mona ^a   Imbert Bismut, Françoise ^a   Charlotte, Frederic ^a   Thabut, Dominique ^a   Le Calvez, Sophie ^a   Messous, Djamila ^a   Thibault, Vincent ^a   Benhamou, Yves ^a   Moussalli, Joseph ^a   Ratziu, Vlad ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HEPATITIS C; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MALE; PREVALENCE; QUALITY CONTROL; RISK FACTOR; STAGING; STEATOSIS;

ADULT; BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INPATIENTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES;

HEPATITIS C VIRUS;

EID: 3242798959     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.032227     Document Type: Article

References (38)

1. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003;37972-4.
2. Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36:S152-60.
3. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
4. Regev A, Berho M, Jeffers U, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
5. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
6. Bedossa P, Dafgère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
7. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543-8.
8. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.
9. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002;36:S161-72.
10. Imbert-Bismut F, Ratziu V, Laurence Pieroni L, Charlotte F, Benhamou Y, Poynard T, the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
11. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepatitis 2002;9:128-33.
12. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:2419-25.
13. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003;17:1-5.
14. Myers RP, de Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and the age-platelet index. Dig Dis Sci 2003;48:146-53.
15. Thabut D, Simon M, Myers RP, Messous D, Thibaut V, Imbert-Bismut F, et al. Non-invasive prediction of fibrosis in patients with chronic hepatitis C [Letter]. Hepatology 2003;37:1220-1.
16. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of Fibrotest vs APRI for the diagnosis of fibrosis in chronic hepatitis C [Letter]. Hepatology 2004;39:862-3.
17. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the interlaboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;1:3-7.
18. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
19. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;8480:523-5.
20. The METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:1:15-20.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
22. Sezer S, Ozdemir FN, Guz G, Ozdemir BH, Sengul S, Arat Z, et al. Ferritin levels can be a good predictor for HCV viremia in potential renal transplant candidates. Transplant Proc 2001;33:2796-8.
23. Vendemiale G, Grattagliano I, Portincasa P, Serviddio G, Palasciamo G, Altomare E. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest 2001;31:54-63.
24. Fabris C, Toniutto P, Scott CA, Falleti E, Avellini C, Del Forno M, et al. Serum iron indices as a measure of iron deposits in chronic hepatitis C. Clin Chim Acta 2001;304:49-55.
25. Romagnuolo J, Jhangri GS, Jewell LD, Bain VG. Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol 2001;96:3165-74.
26. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histologie findings in chronic hepatitis C: a European collaborative study. Hepatology 2002;36:973-7.
27. Hintze JL NCSS 2003 user guide. Kaysville, UT: Number Cruncher Statistical Systems, 2003.
28. Clark GH, Fraser CG. Biological variation of acute phase proteins. Ann Clin Biochem 1993;30:373-6.
29. Maes M, Cooreman W, Delanghe J, Scharpe S, Wauters A, Neels H, et al. Components of biological variation in plasma haptoglobin: relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor. Clin Chim Acta 1995;239:23-35.
30. Borlak J, Thum T, Landt O, Erb K, Hermann R. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology 2000;32:792-5.
31. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or Interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
32. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD) [Abstract]. Hepatology 2003;38:138A.
33. Ratziu V, Lecalvez S, Imbert-Bismut F, Messous D, Charlotte F, Muntenau M, et al. Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) [Abstract]. Hepatology 2003;38:112A.
34. Milotic I, Pavic I, Maleta I, Troselj-Vukic B, Milotic F. Modified range of alanine aminotransferase is insufficient for screening of hepatitis C virus infection in hemodialysis patients. Scand J Urol Nephrol 2002;36:447-9.
35. Poynard T, Imbert-Bismut F, Ratziu V, Naveau S, Thabut D, Lebrec D, et al. An overview of biochemical markers' (Fibrotest-Actitest) diagnostic value in chronic liver diseases: a non-invasive alternative to liver biopsy [Abstract]. Hepatology 2003;38:559A.
36. Thabut D, Imbert-Bismut F, Cazals-Athem D, Moreau R, Messous D, Ratziu V, et al. Diagnostic value of fibrosis biochemical markers (Fibrotest) for the prediction of portal hypertension in liver disease [Abstract]. Hepatology 2003;38:282A.
37. Thabut D, Trabut JB, Le Calvez S, Thibaut V, Massard J, d'Arondel C et al. Diagnostic value of fibrosis biochemical markers (Fibrotest) for the screening of oesophageal varices in patients with chronic liver disease [Abstract]. Hepatology 2003;38:284A.
38. Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and references ranges in healthy blood donors. Clin Chem Lab Med 2004;42:323-33.